Exactis is pleased to be working with Dr. Jonathan Spicer on a phase I interventional pilot open-label trial, using rhDNase1 as a treatment for COVID-19 positive patients.
The objectives are to assess the safety and feasibility of inhaled rhDNase1 in severely ill COVID-19 patients requiring admission, to evaluate the impact of rhDNase1 in limiting progression of disease and COVID-19-related complications in these patients, and to investigate NETs as possible therapeutic targets in severe COVID-19 patients by quantifying levels of circulating NETs in the blood.
Full Article: https://clinicaltrials.gov/ct2/show/NCT04409925?term=Exactis&draw=2&rank=2